Abstract
HM70186, a medoxomil ester of EXP3174 which is an active metabolite of angiotensin II receptor blocker losartan, was synthesized, and its antihypertensive efficacy was evaluated in rats with hepatic dysfunction. Male Wistar rats were intraperitoneally injected with 0.5 mL/kg of carbon tetrachloride to cause hepatic injury, and implanted with an osmotic minipump containing angiotensin II (0.4 mg/kg/day) to induce hypertension. After confirmation of both hepatic damage and hypertension, the rats were orally administered losartan or HM70186, and then blood pressure and heart rate were monitored for 24 h. In normal animals, angiotensin II-induced hypertension was lowered by losartan, resulting in an ED−30 mmHg of 9.05 mg/kg. HM70186 also immediately decreased the blood pressure in a dose-dependent manner, exhibiting an ED−30 mmHg of 0.89 ng/kg (10,000 times the potency observed with losartan). Moreover, HM70186 (3 ng/kg) exerted a strong antihypertensive effect even in rats with hepatic injury, while losartan (10 μg/kg) was ineffective. These results suggest that HM70186 could be a promising candidate for the treatment of hypertension accompanied by hepatic dysfunction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cangiano, J. L., Rodriguez-Sargent, C., and Martinez-Maldonado, M., Effects of antihypertensive treatment on systolic blood pressure and rennin in experimental hypertension in rats. J. Pharmacol. Exp. Ther., 208, 310–313 (1979).
Cody, R. J., Haemodynamic responses to specific reninangiotensin inhibitors in hypertension and congestive heart failure. Drugs, 28, 144–169 (1984).
Croquet, V., Moal, F., Veal, N., Wang, J., Oberti, F., Roux, J., Vuillemin, Y., Douay, O., Chappard, D., and Cales, P., Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. J. Hepatol., 37, 773–780 (2002).
Eyer, J., Hypertension as a disease of modern society. Int. J. Health Serv., 5, 539–558 (1975).
Fink, G. D., Long-term sympatho-excitatory effect of angiotensin II: a mechanism of spontaneous and renovascular hypertension. Clin. Exp. Pharmacol. Physiol., 24, 91–95 (1997).
Gridendling, K. K., Lassegue, B., Murphy, T. J., and Alexander, R. W., Angiotensin II receptor pharmacology. Adv. Phamacol., 28, 269–306 (1994).
Lee, B. H., Seo, H. W., Kwon, K. J., Yoo, S. E., and Shin, H. S., In vivo pharmacology profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist. J. Cardiovasc. Pharmacol., 33, 375–382 (1999).
Merck & Co., Inc., Center for drug evaluation and research approval package for: Appilcation number 20-386/S-032 (1995).
Pals, D. T., Masucci, F. D., Denning, G. S., Jr., Sipos, F., and Fessler, D. C., Role of the pressor action of angiotensin II in experimental hypertension. Circ. Res., 29, 673–681 (1971).
Ritz, E., Total cardiovascular risk management. Am. J. Cardiol., 100, 53J–60J (2007).
Sarr, M., Chataigneau, M., Martins, S., Schott, C., El Bedoui, J., Oak, M. -H., Muller, B., Chataigneau, T., and Schini-Kerth, V. B., Red wine polyphenols prevent angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase. Cardiovasc. Res., 71, 794–802 (2006).
Smith, R. D., Chiu, A. T., Wong, P. C., Herbin, W. F., and Timmermans, P. B., Phamacology of nonpeptide angiotensin II receptor antagonists. Annu. Rev. Pharmacol. Toxicol., 32, 135–165 (1992).
Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., Lee, R. J., Wexler, R. R., Saye, J. A., and Smith, R. D., Angiotensin II receptors and angiotensin II receptor antagonists. Phamacol. Rev., 45, 205–251 (1993).
Wong, P. C., Price, W. A., Jr., Chiu, A. T., Carini, D. J., Duncia, J. V., Johnson, A. L., Wexler, R. R., and Timmermans, P. B., Nonpeptide angiotensin II receptor antagonists. Studies with EXP9270 and DuP753. Hypertension, 15, 823–834 (1990a).
Wong, P. C., Price, W. A., Jr., Chiu, A. T., Duncia, J. V., Carini, D. J., Wexler, R. R., Johnson, A. L., and Timmermans, P. B., Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther., 255, 211–217 (1990b).
Wong, P. C., Price, W. A., Chiu, A. T., Duncia, J. V., Carini, D. J., Wexler, R. R., Johnson, A. L., and Timmermans, P. B., Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP753, an orally active antihypertensive agent. J. Pharmacol. Exp. Ther., 252, 726–732 (1990c).
Wong, P. C., Price, W. A., Jr., Chiu, A. T., Duncia, J. V., Carini, D. J., Wexler, R. R., Johnson, A. L., and Timmermans, P. B., In vivo pharmacology of DuP753. Am. J. Hypertens., 4, 288S–298S (1991).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Choi, JH., Shin, S., Park, D. et al. Comparative antihypertensive activities of losartan and HM70186 in rats with hepatic dysfunction. Arch. Pharm. Res. 32, 1005–1011 (2009). https://doi.org/10.1007/s12272-009-1705-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-009-1705-0